Background: The fractional concentration of exhaled nitric oxide (FeNO) is a surrogate biomarker for Th2-dependent bronchial inflammation. The present study investigated whether FeNO may characterize allergic rhinitis (AR) patients.
Methods: A total of 553 AR patients (497 males, mean age 28.8 years) were evaluated. Those patients with a high FeNO underwent a 2-year follow-up.
Results: Increased FeNO was associated with a significantly longer AR duration, impaired lung function, more severe symptoms, and more frequent bronchial hyperresponsiveness (BHR). At follow-up, 22 out of 82 patients (26.8%) with high FeNO levels (>50 ppb) developed asthma.
Conclusions: AR patients may frequently have high FeNO values, exceeding 50 ppb. This might be associated with an initial impaired lung function, BHR, a perceived worsening of respiratory symptoms, and potential progression to asthma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000456548 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Small airway dysfunction mediates the relationship between FeNO and asthma control.
Ann Allergy Asthma Immunol
January 2025
Center for Medical Sciences (CISMed), Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Italy; Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari (APSS) Trento, Italy. Electronic address:
Background: Most of the Fractional exhaled Nitric Oxide (FeNO)'s physiological production occurs in small airways, but the relationship between FeNO and small airway disease (SAD) in asthma is scant.
Objective: To investigate the relationship between asthma control, changes of FeNO in relation to airway bronchodilation (BD), and SAD.
Methods: Baseline conventional spirometry, impulse oscillometry (IOS), and FeNO pre- and post-bronchodilation (salbutamol 400 mcg) were tested on consecutive community-treated adult asthmatic patients.
The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis.
Respir Med
January 2025
Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address:
Background: The ORBE II study showed the real-world effectiveness of benralizumab in severe eosinophilic asthma (SEA). This subgroup analysis aimed to characterize patients and outcomes based on baseline blood eosinophil count (BEC) and/or fractional exhaled nitric oxide (FeNO) levels.
Methods: In this analysis of the ORBE II retrospective study, SEA patients receiving benralizumab were categorized into subgroups based on individual or combined BEC/FeNO levels, according to the following thresholds: high BEC (hiBEC): ≥300 cells/μL; low BEC (loBEC): <300 cells/μL; high FeNO (hiFeNO): ≥50 ppb; low FeNO (loFeNO): <50 ppb.
Traffic-related air pollution (TRAP) exposure, lung function, airway inflammation and expiratory microbiota: A randomized crossover study.
Ecotoxicol Environ Saf
January 2025
College of Environmental Science and Engineering, Tongji University, Shanghai 200092, China; State Key Laboratory of Environmental Criteria and Risk Assessment, Chinese Research Academy of Environmental Sciences, Beijing 100012, China. Electronic address:
Traffic-related air pollution (TRAP) has been linked with numerous respiratory diseases. Recently, lung microbiome is proposed to be characterized with development and progression of respiratory diseases. However, the underlying effects of TRAP exposure on lung microbiome are rarely explored.
View Article and Find Full Text PDFPre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics.
J Asthma
January 2025
Division of Pneumology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU Sant'Andrea, Rome, Italy.
Objective: It remains unclear whether baseline FeNO levels can predict response to anti-IL5/5R biologic treatment in patients with severe asthma.
Methods: We recruited 104 patients with severe eosinophilic asthma treated with anti-IL5/anti-IL5R for at least one year who had measured FeNO values before the beginning of anti-eosinophilic treatment. Population was divided into subjects with FeNO < 25 and ≥25 ppb.
Characterization of Serum Cytokine Patterns in Frequent-Exacerbation Asthma: Implications for Phenotyping and Management.
Adv Respir Med
December 2024
Respiratory Center, Military Hospital 103, Vietnam Military Medical University, Hanoi 12100, Vietnam.
(1) Background: Asthma exacerbations represent significant clinical events, however, the underlying inflammatory mechanisms and cytokine profiles in patients with frequent exacerbations remain incompletely understood; (2) Methods: In this prospective, cross-sectional study of 120 stable asthma patients, we compared the serum concentrations of eight key cytokines (IL-4, IL-12, IL-13, IL-17, IFN-α, IFN-γ, TNF-α, and IL-1β) between two groups: 60 patients with frequent exacerbations (≥ 2 events per year) and 60 matched controls with few exacerbations (1 event per year); (3) Results: Patients with frequent exacerbations showed significantly higher serum concentrations of IL-4 and IL-13 ( < 0.05), along with an increased prevalence of allergic history and comorbidities (chronic rhinosinusitis, GERD, OSA; all < 0.05).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!